Altimmune, Inc.
ALTNext catalyst
Pemvidutide
Alcohol Use Disorder (AUD)
Get an email about ALT's next catalysts
Track Altimmune (ALT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Pemvidutide Phase 2 Est. Readout
Estimated primary completion for Pemvidutide trial (NCT07009860) in Alcohol-associated Liver Disease. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pemvidutide | Phase 3 | Alcohol Use Disorder (AUD) | - | - |
ALT-801 | Phase 2 | Obesity/Overweight | - | - |
NasoVAX | Phase 2 | Influenza | - | - |
Frequently asked questions
What is in Altimmune, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Altimmune, Inc.'s (ALT) pipeline across Phase 3, Phase 2. Its lead program is Pemvidutide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Altimmune, Inc.'s next FDA catalyst?→
Altimmune, Inc.'s (ALT) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALT biotech catalysts?→
Add ALT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Altimmune, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.